Zolpidem

Zolpidem reduces respiratory drive via brainstem GABAergic inhibition. In patients with severe respiratory insufficiency or neuromuscular respiratory compromise, even modest respiratory depression may be clinically significant.

Limited data suggest zolpidem does not significantly reduce CPAP efficacy, but respiratory depression risk warrants caution in patients with untreated or severe OSA, particularly when combined with other sedating agents.

Patients who have experienced sleepwalking, sleep-driving, sleep-eating, or other complex behaviors on zolpidem must not be re-exposed. The susceptibility factors are uncharacterized and recurrence is unpredictable.

Patients with myasthenia gravis may experience worsened muscle weakness and respiratory compromise with GABAergic sedative-hypnotics.

Zolpidem produces dose-dependent euphoria, drug liking, and reinforcement at supratherapeutic doses. Patients with active substance use disorders are at elevated risk for dose escalation, recreational misuse, and dependence.

Severe hepatic impairment produces dangerously elevated and prolonged plasma concentrations. Dose adjustment alone is insufficient in severe disease.

Zolpidem crosses the placental barrier and may cause neonatal respiratory depression and sedation. Use during pregnancy should be avoided unless clearly necessary, with the lowest effective dose for the shortest duration.

The compound is present in breast milk. Temporary cessation of breastfeeding is recommended following zolpidem administration to minimize infant exposure.

Elderly patients have prolonged zolpidem exposure due to decreased hepatic clearance and increased CNS sensitivity. Fall-related fracture risk is disproportionately elevated. AASM guidelines recommend the lowest effective dose (5 mg) or avoidance in older adults.

Zolpidem is not approved for use in children. Despite approximately 3× higher clearance in children than young adults, hallucinations and paradoxical excitation have been reported. No pediatric efficacy or safety data from controlled trials.

Anaphylaxis and angioedema have been reported. Any prior hypersensitivity reaction to zolpidem or its excipients is an absolute contraindication to re-exposure.